CSPC2016 has ended
avatar for Jim Woodgett

Jim Woodgett

Mount Sinai Hospital
Director of the Lunenfeld-Tanenbaum Research Institute,
Jim Woodgett, Ph.D. (Dundee U) moved to Canada in 1992 to work at the Ontario Cancer Institute. His biomedical research there focused on the signalling mechanisms that underscore malignant growth, degenerative diseases and diabetes.

From 1995-2005, he was an International Scholar of the Howard Hughes Medical Institute and in 1997 was appointed Head of the Division of Experimental Therapeutics, where he held the Amgen Chair of Cancer Biology. A full professor in the department of medical biophysics at the University of Toronto, he has been an MRC Scientist and CIHR Senior Scientist and is known internationally for his work on a class of proteins that regulate cellular processes, termed protein kinases. In 2005 he was appointed as the fourth Director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital (now called the Lunenfeld-Tanenbaum Research Institute).

He is a fellow of the Royal Society of Canada and holds the Koffler Chair at Sinai Health System. His current research involves understanding mechanisms leading to diabetes, brain development/ Alzheimers disease, as bipolar disorder. Although he holds a CIHR Foundation scheme grant, he remains extremely concerned about how health research is now being adjudicated by CIHR.